aap concludes distribution agreement for LOQTEQ® VA Radius System with leading global spine and orthopedics company

EQS-News: aap Implantate AG

/ Key word(s): Alliance

aap concludes distribution agreement for LOQTEQ® VA Radius System with leading global spine and orthopedics company

09.01.2024 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap”) announces the conclusion of a distribution agreement for its LOQTEQ® VA Radius System with a leading global spine and orthopedics company.

The distribution agreement for the LOQTEQ® VA Radius System, the top selling product of aap`s anatomical plates and screws portfolio, is exclusively distributed in the entire territory of France and has a five-year term with a renewal option and an expected business volume of around EUR 2.0 – 2.5 million for the initial term with potential upsides.

The conclusion of the agreement represents further important progress in the aimed distribution focus in established markets and will sustainably strengthen the planned sales growth.








aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German Stock Exchanges –


About aap Implantate AG

aap Implantate AG is a globally active medical technology company headquartered in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. This involves sales both via distribution agents and as part of partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.


The figures presented in this press release may be subject to technical rounding differences which do not affect the overall presentation.


Forward-looking statements

This release may contain forward-looking statements based on current expectations, beliefs and projections of the Management Board and currently available information. The forward-looking statements are not guarantees of future performance or results. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in aap’s public reports. Forward-looking statements therefore speak only as of the date they are made. We assume no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.


If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo, Chairman of the Management Board, CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 294; Fax: +49 (0)30 75019 – 290; E-Mail: r.digirolamo@aap.de

09.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

show this